465 related articles for article (PubMed ID: 16846617)
1. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
2. Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats.
Mucha S; Melen-Mucha G; Stepien T; Godlewski A; Stepien H
Oncol Rep; 2002; 9(6):1385-9. PubMed ID: 12375053
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.
Mucha SA; Meleń-Mucha G; Godlewski A; Stepień H
Virchows Arch; 2007 Mar; 450(3):335-41. PubMed ID: 17235567
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects.
Gruszka A; Pawlikowski M; Kunert-Radek J
Neuro Endocrinol Lett; 2001 Oct; 22(5):343-8. PubMed ID: 11600876
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Grochal M; Zieliński KW; Mucha S; Kunert-Radek J; Kulig A; Stawowy A; Pisarek H
J Endocrinol; 1996 Jul; 150(1):99-106. PubMed ID: 8708569
[TBL] [Abstract][Full Text] [Related]
7. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor.
Banerjeei SK; Zoubine MN; Sarkar DK; Weston AP; Shah JH; Campbell DR
Anticancer Res; 2000; 20(4):2641-5. PubMed ID: 10953337
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal polypeptide antiserum affects rat prolactin mRNA in 40-day but not 110-day diethylstilbestrol-induced prolactinoma tissue.
Maas DL; Meier DA; Wahle JS; Martinson DR; Hagen TC
Mol Cell Neurosci; 1994 Apr; 5(2):182-8. PubMed ID: 8032686
[TBL] [Abstract][Full Text] [Related]
9. Estrogen induction of prolactin-producing pituitary tumors in the Fischer 344 rat: modulation by dietary-energy but not protein consumption.
Shull JD; Birt DF; McComb RD; Spady TJ; Pennington KL; Shaw-Bruha CM
Mol Carcinog; 1998 Oct; 23(2):96-105. PubMed ID: 9808163
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of melatonin on the growth of pituitary prolactin-secreting tumor in rats.
Yang QH; Xu JN; Xu RK; Pang SF
J Pineal Res; 2006 Apr; 40(3):230-5. PubMed ID: 16499559
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
Gruszka A; Kunert-Radek J; Pawlikowski M
Neuro Endocrinol Lett; 2005 Feb; 26(1):51-4. PubMed ID: 15726020
[TBL] [Abstract][Full Text] [Related]
12. The Edpm5 locus prevents the 'angiogenic switch' in an estrogen-induced rat pituitary tumor.
Pandey J; Bannout A; Wendell DL
Carcinogenesis; 2004 Oct; 25(10):1829-38. PubMed ID: 15166088
[TBL] [Abstract][Full Text] [Related]
13. Effects of estrogen and tamoxifen on the ultrastructural characteristics of female rat prolactin cells as evaluated by immunogold technique.
Erensoy N; Cagatay P; Yilmazer S
Acta Histochem; 2005; 107(3):199-205. PubMed ID: 15993477
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro.
Yang QH; Xu JN; Xu RK; Pang SF
J Pineal Res; 2007 Mar; 42(2):172-9. PubMed ID: 17286750
[TBL] [Abstract][Full Text] [Related]
15. Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen.
Gómez O; Balsa JA
Endocrinology; 2003 Oct; 144(10):4403-9. PubMed ID: 12960047
[TBL] [Abstract][Full Text] [Related]
16. Glandular kallikrein in estrogen-induced pituitary tumors: time course of induction and correlation with prolactin.
Hatala MA; Powers CA
Cancer Res; 1988 Aug; 48(15):4158-62. PubMed ID: 3390808
[TBL] [Abstract][Full Text] [Related]
17. The effect of somatostatin analog octreotide on diethylstilbestrol-induced prolactin secretion, cell proliferation and vascular changes in the rat anterior pituitary gland.
Pawlikowski M; Kunert-Radek J; Grochal M; Zieliński K; Kulig A
Histol Histopathol; 1997 Oct; 12(4):991-4. PubMed ID: 9302560
[TBL] [Abstract][Full Text] [Related]
18. Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression.
Gómez O; Balsa JA
Neuroendocrinology; 2004; 80(5):324-31. PubMed ID: 15677882
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. An immunohistochemical study.
Lloyd RV
Am J Pathol; 1983 Nov; 113(2):198-206. PubMed ID: 6638150
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of prolactin secretion from diethylstilbestrol-induced rat prolactinoma tissue in vitro.
Maas DL; Martinson DR; Erdmann MD; Wahle JS; Hagen TC
Proc Soc Exp Biol Med; 1995 Nov; 210(2):150-5. PubMed ID: 7568285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
